This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2010 May;87(5):527-9.

doi: 10.1038/clpt.2010.30.

Arguments against precompetitive collaboration

G Vargas¹, B Boutouyrie, S Ostrowitzki, L Santarelli

Affiliations

PMID: 20407456
DOI: 10.1038/clpt.2010.30

Review

Arguments against precompetitive collaboration

G Vargas et al. Clin Pharmacol Ther. 2010 May.

. 2010 May;87(5):527-9.

doi: 10.1038/clpt.2010.30.

Authors

G Vargas¹, B Boutouyrie, S Ostrowitzki, L Santarelli

Affiliation

¹ F. Hoffmann-La Roche Ltd., Basel, Switzerland.

PMID: 20407456
DOI: 10.1038/clpt.2010.30

No abstract available

PubMed Disclaimer

Similar articles

Open-minded to open innovation and precompetitive collaboration.
Wagner JA. Wagner JA. Clin Pharmacol Ther. 2010 May;87(5):511-5. doi: 10.1038/clpt.2010.39. Clin Pharmacol Ther. 2010. PMID: 20407451 Review. No abstract available.
The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
Wagner JA, Prince M, Wright EC, Ennis MM, Kochan J, Nunez DJ, Schneider B, Wang MD, Chen Y, Ghosh S, Musser BJ, Vassileva MT. Wagner JA, et al. Clin Pharmacol Ther. 2010 May;87(5):539-42. doi: 10.1038/clpt.2009.227. Clin Pharmacol Ther. 2010. PMID: 20407460 Review.
How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED, Van Dam J, Szalma S. Perakslis ED, et al. Clin Pharmacol Ther. 2010 May;87(5):614-6. doi: 10.1038/clpt.2010.21. Epub 2010 Apr 7. Clin Pharmacol Ther. 2010. PMID: 20376001 Review. No abstract available.
The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
Woosley RL, Myers RT, Goodsaid F. Woosley RL, et al. Clin Pharmacol Ther. 2010 May;87(5):530-3. doi: 10.1038/clpt.2010.27. Clin Pharmacol Ther. 2010. PMID: 20407457 Review.
Precompetitive research: a new prescription for drug development?
Woodcock J. Woodcock J. Clin Pharmacol Ther. 2010 May;87(5):521-3. doi: 10.1038/clpt.2010.28. Clin Pharmacol Ther. 2010. PMID: 20407454 No abstract available.

See all similar articles

Cited by

Pharma embraces open source models.
Strauss S. Strauss S. Nat Biotechnol. 2010 Jul;28(7):631-4. doi: 10.1038/nbt0710-631. Nat Biotechnol. 2010. PMID: 20622810 No abstract available.
Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.
Mahajan R, Gupta K. Mahajan R, et al. J Pharm Bioallied Sci. 2010 Oct;2(4):307-13. doi: 10.4103/0975-7406.72130. J Pharm Bioallied Sci. 2010. PMID: 21180462 Free PMC article.
Empowering industrial research with shared biomedical vocabularies.
Harland L, Larminie C, Sansone SA, Popa S, Marshall MS, Braxenthaler M, Cantor M, Filsell W, Forster MJ, Huang E, Matern A, Musen M, Saric J, Slater T, Wilson J, Lynch N, Wise J, Dix I. Harland L, et al. Drug Discov Today. 2011 Nov;16(21-22):940-7. doi: 10.1016/j.drudis.2011.09.013. Epub 2011 Sep 23. Drug Discov Today. 2011. PMID: 21963522 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley